- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02502474
Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne (ColoStaph)
September 27, 2018 updated by: Centre Hospitalier Universitaire de Saint Etienne
Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne.
Epidemiological study aiming to describe the carriage (nasal, throat, groin, rectal and colonic) of S. aureus in patients without chronic digestive disease who are going to have a colonoscopy for cancer screening.
The carriage will be analyzed globally and the similarity of strains isolated from each site will be analyzed using molecular tools.
The aim of this study is to better estimate the digestive reservoir of S. aureus to better prevent endogenous infections due to this bacterium.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
112
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Saint-Etienne, France, 42055
- CHU Saint-Etienne
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient affiliated to French social security
- Written consent of the patient
- Patient needing a colonoscopy in the University Hospital of Saint-Etienne, France
Exclusion Criteria:
- Patient who decline to participate to the study
- Patient in the incapacity to give consent
- Patient receiving treatment with anticoagulant or antiaggregant platelets
- Patients with a known haemostatic disorder
- Pregnant woman
- Patients with a chronic disease of the gastrointestinal tract
- Patients receiving long-term corticosteroid
- Patient receiving anti staphylococcal antibiotics
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients undergoing a colonoscopy
Staphylococcus aureus carriage is measured in nose, throat, colon, rectum and groin
|
nasal, throat, rectal and groin sampling with swabs.
Colonic sampling by colonic biopsy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patient with Staphylococcus aureus colonic carriage
Time Frame: Day 1
|
Staphylococcus aureus carriage in the colon is measured by biopsy
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patient with similar Staphylococcus aureus strains in the nose and in the rectum
Time Frame: Day 1
|
Staphylococcus aureus carriage in the rectum and in the nose is measured by swab culture
|
Day 1
|
Number of patient with Staphylococcus aureus carriage in the nose
Time Frame: Day 1
|
Staphylococcus aureus carriage in the nose is measured by swab culture.
|
Day 1
|
Number of patient with Staphylococcus aureus carriage in the throat
Time Frame: Day 1
|
Staphylococcus aureus carriage in the throat is measured by swab culture.
|
Day 1
|
Number of patient with Staphylococcus aureus carriage in the groin
Time Frame: Day 1
|
Staphylococcus aureus carriage in the groin is measured by swab culture.
|
Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Philippe Berthelot, PhD, CHU Saint-Etienne
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 2, 2015
Primary Completion (Actual)
October 20, 2017
Study Completion (Actual)
October 20, 2017
Study Registration Dates
First Submitted
July 15, 2015
First Submitted That Met QC Criteria
July 16, 2015
First Posted (Estimate)
July 20, 2015
Study Record Updates
Last Update Posted (Actual)
September 28, 2018
Last Update Submitted That Met QC Criteria
September 27, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1408023
- 2014-A00755-42 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on STAPHYLOCOCCAL INFECTIONS
-
GlaxoSmithKlineCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcal InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedStaphylococcal Infection
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcal InfectionUnited States
-
Destiny Pharma PlcCompletedStaphylococcal InfectionUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedMethicillin-resistant Staphylococcal InfectionsFrance
-
Aaron ChenJohns Hopkins University; Thrasher Research FundCompletedStaphylococcal Skin Infection | Abscess | Staphylococcal Infection | FolliculitisUnited States
-
National Institute of Allergy and Infectious Diseases...TerminatedStaphylococcal Aureus Infection | Recurrent Staphylococcal Infection | Invasive Staphylococcal InfectionUnited States
-
Nantes University HospitalCompleted
-
Erasme University HospitalCompletedStaphylococcus Aureus | Staphylococcal Infection | Methicillin ResistanceBelgium
Clinical Trials on Staphylococcus aureus carriage
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Nantes University HospitalCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Jiangsu Province Centers for Disease Control and...Third Military Medical University; Chengdu Olymvax Biopharmaceuticals Inc.CompletedStaphylococcus Aureus InfectionChina
-
Jiangsu Province Centers for Disease Control and...Third Military Medical University; Chengdu Olymvax Biopharmaceuticals Inc.CompletedStaphylococcus Aureus InfectionChina
-
Jiangsu Province Centers for Disease Control and...Chengdu Olymvax Biopharmaceuticals Inc.; PLA Army Medical UniversityCompletedStaphylococcus Aureus InfectionChina
-
PfizerCompletedStaphylococcal InfectionsJapan
-
AbbVieRecruitingIrritable Bowel SyndromeUnited States, Canada, Poland, United Kingdom, Hungary, Bulgaria, Netherlands
-
Pherecydes PharmaRecruitingInfection of Total Hip Joint Prosthesis | Infection of Total Knee Joint ProsthesisFrance
-
Merck Sharp & Dohme LLCTerminatedBacteremia | Staphylococcus Aureus | Mediastinitis